11/30
05:51 am
aclx
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]
Medium
Report
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]
11/24
03:08 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
11/24
03:08 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.
11/18
04:13 pm
aclx
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition [Yahoo! Finance]
Low
Report
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition [Yahoo! Finance]
11/18
04:00 pm
aclx
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
Low
Report
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
11/18
09:00 am
aclx
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/7
03:36 pm
aclx
How Investors Are Reacting To Arcellx (ACLX) Missing Revenue Estimates and Reporting Wider Losses [Yahoo! Finance]
Low
Report
How Investors Are Reacting To Arcellx (ACLX) Missing Revenue Estimates and Reporting Wider Losses [Yahoo! Finance]
11/5
04:00 pm
aclx
Arcellx Provides Third Quarter 2025 Financial Results
Low
Report
Arcellx Provides Third Quarter 2025 Financial Results
11/3
09:00 am
aclx
Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition
Low
Report
Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition
11/3
08:33 am
aclx
Arcellx (NASDAQ:ACLX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $121.00 to $130.00. They now have a "buy" rating on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $121.00 to $130.00. They now have a "buy" rating on the stock.
10/16
09:05 am
aclx
Arcellx (NASDAQ:ACLX) was given a new $129.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) was given a new $129.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.
10/10
06:49 am
aclx
Arcellx (NASDAQ:ACLX) was downgraded by analysts at Cantor Fitzgerald from a "strong-buy" rating to a "hold" rating.
Low
Report
Arcellx (NASDAQ:ACLX) was downgraded by analysts at Cantor Fitzgerald from a "strong-buy" rating to a "hold" rating.
10/10
04:49 am
aclx
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook [Yahoo! Finance]
Low
Report
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook [Yahoo! Finance]
10/9
09:16 am
aclx
Arcellx (NASDAQ:ACLX) was given a new $88.00 price target on by analysts at Cantor Fitzgerald.
Low
Report
Arcellx (NASDAQ:ACLX) was given a new $88.00 price target on by analysts at Cantor Fitzgerald.
10/8
01:24 pm
aclx
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight [Yahoo! Finance]
Low
Report
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight [Yahoo! Finance]
10/3
03:30 pm
aclx
Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.